Real-world safety of nivolumab in patients with non-small cell lung cancer (NSCLC) in Japan: Interim summary of post-marketing all-case surveillance

被引：0
|
作者：
Ohe, Y. [1 ]
Gemma, A. [2 ]
Nakagawa, K. [3 ]
Yamamoto, N. [4 ]
Saito, T. [5 ]
Akamatsu, A. [5 ]
Kuwano, K. [6 ]
Nakanishi, Y. [7 ]
机构：
[1] Natl Canc Ctr, Pulm Med, Tokyo, Japan
[2] Nippon Med Sch, Dept Pulm Med & Oncol, Tokyo, Japan
[3] Kindai Univ, Fac Med, Dept Internal Med, Osaka, Japan
[4] Wakayama Med Univ, Pulm Med, Wakayama, Japan
[5] Ono Pharmaceut Co Ltd, Pharmacovigilance Div, Osaka, Japan
[6] Jikei Univ, Pulm Med, Sch Med, Tokyo, Japan
[7] Kyushu Univ Hosp, Res Inst Dis Chest, Fukuoka, Fukuoka, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1217P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Safety Profile of Nivolumab in Japanese NSCLC Pts: Interim Results from Post-marketing All-Case Surveillance in Japan
    Genma, Akihiko
    Nakanishi, Yoichi
    Nakagawa, Kazuhiko
    Yamamoto, Nobuyuki
    Saito, Takeshi
    Tahara, Yasuhiro
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] Safety Profile of Nivolumab in Japanese NSCLC Pts: Interim Results from Post-marketing All-Case Surveillance in Japan
    Genma, Akihiko
    Nakanishi, Yoichi
    Nakagawa, Kazuhiko
    Yamamoto, Nobuyuki
    Saito, Takeshi
    Tahara, Yasuhiro
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2017, 28 : 75 - 75
  • [3] Real-world outcomes of pembrolizumab monotherapy in non-small cell lung cancer in Japan: A post-marketing surveillance
    Yamamoto, Nobuyuki
    Kamitani, Tetsu
    Kanda, Kingo
    Ito, Yuichiro
    Hamada, Masahiro
    Ozaki, Masahiko
    Takeuchi, Noriko
    Yamada, Tomoko
    Kawano, Masaki
    Maekawa, Shinichiroh
    Kato, Terufumi
    CANCER SCIENCE, 2022, 113 (09) : 3110 - 3119
  • [4] Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer: A study on risk factors using interim results of post-marketing all-case surveillance.
    Kenmotsu, Hirotsugu
    Sakai, Fumikazu
    Kato, Terufumi
    Kusumoto, Masahiko
    Baba, Tomohisa
    Kuwano, Kazuyoshi
    Gemma, Akihiko
    Nakagawa, Kazuhiko
    Nakanishi, Yoichi
    Yamamoto, Nobuyuki
    Ito, Yoshihiko
    Tahara, Yasuhiro
    Ohe, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] SAFETY AND EFFECTIVENESS OF PEMETREXED IN PATIENTS WITH NON-SMALL CELL LUNG CANCER IN JAPAN BASED ON POST-MARKETING SURVEILLANCE
    Okubo, Sumiko
    Kobayashi, Noriko
    Taketsuna, Masanori
    Enatsu, Sotaro
    Nishiuma, Shinichi
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S485 - S485
  • [6] Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance
    Hirotsugu Uemura
    Yoshihiko Tomita
    Norio Nonomura
    Kenji Yoshizaki
    Takafumi Nakao
    Nobuo Shinohara
    International Journal of Clinical Oncology, 2022, 27 : 1061 - 1067
  • [7] Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance
    Uemura, Hirotsugu
    Tomita, Yoshihiko
    Nonomura, Norio
    Yoshizaki, Kenji
    Nakao, Takafumi
    Shinohara, Nobuo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (06) : 1061 - 1067
  • [8] Real-world safety of nivolumab in patients with non-small-cell lung cancer in Japan: Postmarketing surveillance
    Yamamoto, Nobuyuki
    Nakanishi, Yoichi
    Gemma, Akihiko
    Nakagawa, Kazuhiko
    Sakamoto, Takahiko
    Akamatsu, Ayumi
    Ohe, Yuichiro
    CANCER SCIENCE, 2021, 112 (11) : 4692 - 4701
  • [9] Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study
    Fujimoto, Nobukazu
    Akamatsu, Ayumi
    Honda, Chikara
    Aoki, Miki
    Ohe, Yuichiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024,
  • [10] Real-world safety and effectiveness of anamorelin for cancer cachexia: Interim analysis of post-marketing surveillance in Japan
    Takayama, Koichi
    Kojima, Ai
    Honda, Chikara
    Nakayama, Masahiro
    Kanemata, Satomi
    Endo, Toshimitsu
    Muro, Kei
    CANCER MEDICINE, 2024, 13 (09):
12345